Table 3.
Recent approvals of immunotherapeutic agents for esophageal cancer.
| Adenocarcinoma | Squamous Cell Carcinoma | ||||||
|---|---|---|---|---|---|---|---|
| Treatment | Trial Name | Setting | Approval | Treatment | Trial Name | Setting | Approval |
| Nivolumab | CHECKMATE-577 | Adjuvant (after neoadjuvant chemoradiation + surgery with residual pathological disease) | 2021 (FDA, EMA) | Nivolumab | CHECKMATE-577 | Adjuvant (after neoadjuvant chemoradiation + surgery with residual pathological disease) | 2021 (FDA, EMA) |
| Nivolumab + platine or fluoropyrimidine-based chemotherapy | CHECKMATE-649 | 1st line, metastatic, recurrent or inoperable | 2021 (FDA) | Pembrolizumab + platine or fluoropyrimidine-based chemotherapy | KEYNOTE-590 | 1st line metastatic, recurrent or inoperable | 2021 (FDA, EMA for CPS ≥ 10) |
| Pembrolizumab + platine or fluoropyrimidine-based chemotherapy | KEYNOTE-590 | 1st line, metastatic, recurrent or inoperable | 2021 (FDA, EMA for CPS ≥ 10) | Nivolumab | ATTRACTION-3 | 2nd and further-line metastatic, recurrent or inoperable | 2020 (FDA, EMA) |
| Pembrolizumab | KEYNOTE-181 | 2nd and further-line metastatic, recurrent or inoperable, CPS ≥ 10 | 2019 (FDA) | ||||